As Wall Street rebounds on hopes of a shutdown resolution, investors turn to value picks like LTH, CAH, MCK and FLS with strong interest coverage ratios.
Does Cardinal Health (CAH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cardinal Health (CAH) is evolving into a specialty-focused healthcare leader, leveraging acquisitions and managed services for higher profitability and efficiency. CAH's financials show strong gross profit and net income growth, with operational leverage and robust free cash flow supporting ongoing investments and shareholder returns. Despite solid fundamentals, CAH trades at significant valuation discounts to peers.
Cardinal Health CEO Jason Hollar discusses medication affordability, the Obamacare subsidies battle and more on 'The Claman Countdown.' #fox #media #us #usa #new #news #foxbusiness #healthcare #medicine #pharma #affordability #obamacare #insurance #subsidies #economy #business #finance #medical #drugs #hospitals #patients #policy #government #health #usnews #governmentshutdown
Cardinal Health, Inc. ( CAH ) Q1 2026 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Matt Sims - Vice President of Investor Relations Jason Hollar - CEO & Director Aaron Alt - Chief Financial Officer Conference Call Participants Erin Wilson Wright - Morgan Stanley, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Michael Cherny - Leerink Partners LLC, Research Division George Hill - Deutsche Bank AG, Research Division Eric Percher - Nephron Research LLC Allen Lutz - BofA Securities, Research Division Kevin Caliendo - UBS Investment Bank, Research Division Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division Daniel Grosslight - Citigroup Inc., Research Division Steven Valiquette - Mizuho Securities USA LLC, Research Division Jack Slevin - Jefferies LLC, Research Division Presentation Operator Hello, and welcome to the First Quarter Fiscal Year 2026 Cardinal Health, Inc. Earnings Conference Call.
Cardinal Health delivered a strong Q1 beat and lifted its 2026 EPS outlook, fueled by broad-based growth and rising profits across all business segments.
Cardinal Health (NYSE: CAH) delivered a commanding first quarter for fiscal 2026, beating both earnings and revenue expectations by wide margins while raising full-year guidance.
While the top- and bottom-line numbers for Cardinal (CAH) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.